Crucell N.V. has announced that a monoclonal antibody that is active against H5N1 avian influenza has been discoveres by its researchers.
The information regarding this study will be presented at the 5th International Bird Flu Summit from 27-28 September in Las Vegas, Nevada.
Crucell researchers produced antibodies in PERC6 cells and tested their biophysical and immunological properties.
“Using phage display technology a set of human monoclonal antibodies active against a broad range of distinct H5N1 strains was developed,” said Crucell chief scientific officer Dr Jaap Goudsmit. “We will show the ability of these antibodies to prevent infection as well as to prevent and cure disease caused by H5N1 virus in mice.”
5th International Bird Flu Summit